LifeSci Capital initiated coverage of Liquidia with an Outperform rating and $30 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LQDA:
- Liquidia and Pharmosa Biopharm amend exclusive licensing agreement
- Liquidia says court finds United’s interference caused losses over $137M
- Liquidia announces raise of $67.5M from common stock financings
- Biotech Alert: Searches spiking for these stocks today
- Liquidia challenges FDA decision on Yutrepia exclusivity
Questions or Comments about the article? Write to editor@tipranks.com